 Biofrontera AG NASDAQ: BFRA; Frankfurt Stock Exchange: B8F the Company, an international biopharmaceutical company, today reports preliminary unaudited revenue for the first three months of fiscal year 2020. The preliminary unaudited revenue of the Company for the period January 1 to March 31, 2020 was in the range of EUR 6.4 to 6.6 million. The current COVID-19 pandemic had a major impact on the Companys business, with very little sales in particular in the second half of March. 